Primary pulmonary tuberculosis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

10 events
Sep 2026AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT

Ministry of Health, Saudi Arabia — PHASE2

TrialNOT YET RECRUITING
Sep 2026The Feasibility and Acceptability of a Post-tuberculosis Lung Disease Diagnostic Algorithm in Uganda.

Mbarara University of Science and Technology — NA

TrialNOT YET RECRUITING
Feb 2026Effect of Peer-led Educational Intervention on Treatment Outcomes Among Adults With Drug-susceptible Pulmonary Tuberculosis in South Omo and Ari Zone, Southern Ethiopia

Bahirdar University — NA

TrialNOT YET RECRUITING
Feb 2026Remimazolam for Bronchoscopy in High-Risk Patients

First Affiliated Hospital of Zhejiang University — PHASE4

TrialRECRUITING
Feb 2026Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease

Hamilton Health Sciences Corporation — PHASE3

TrialNOT YET RECRUITING
Feb 2026Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -

Research Center Borstel

TrialNOT YET RECRUITING
Jan 2026Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis

Riphah International University — NA

TrialRECRUITING
Jan 2026PRIFTIN: New indication approved
FDAcompleted
Jan 2026ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)

Obafemi Awolowo University Teaching Hospital — PHASE2

TrialRECRUITING
Jan 2026Evaluation of PATHFAST-LAM as a Tuberculosis Treatment Monitoring Tool in Kenya

Nagasaki University

TrialNOT YET RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

2 programs

FINANCIAL LANDSCAPE SUMMARY

2

Total programs

2

Open now

2

Copay cards

Copay Assistance2

RIFAMPIN

SANOFI

OpenContact for detailsApply ↗

Pretomanid

Viatris

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Priftin

(Rifapentine)Orphan drug

Hoechst Marion Roussel

Rifamycin Antimycobacterial [EPC]

12.1 Mechanism of Action Rifapentine, a cyclopentyl rifamycin, is an antimycobacterial agent [see Microbiology (12.4) ] .

Approved Jun 1998FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

23 active trials
5Phase 3
2Phase 4
8Phase 2
4N/A
4Unknown
23Total recruiting
Search clinical trials for Primary pulmonary tuberculosis

Recent News & Research

No recent news articles indexed yet for Primary pulmonary tuberculosis.
Search PubMed for Primary pulmonary tuberculosis

Browse all Primary pulmonary tuberculosis news →

Specialist Network

Top 6 by expertise

View all Primary pulmonary tuberculosis specialists →

Quick Actions